What should be the primary target of "treat to target" in psoriatic arthritis?

What should be the primary target of "treat to target" in psoriatic arthritis?

<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...

Полное описание

Библиографические подробности
Главные авторы:	Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS
Формат:	Journal article
Язык:	English
Опубликовано:	Journal of Rheumatology 2018

Схожие документы

What should be the primary target of ‘treat to target’ in PsA?
по: Coates, L, и др.
Опубликовано: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
по: Coates, L, и др.
Опубликовано: (2022)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
по: Coates, L, и др.
Опубликовано: (2019)

Sustained very low disease activity and remission in psoriatic arthritis patients
по: Lubrano, E, и др.
Опубликовано: (2019)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
по: Lubrano E, и др.
Опубликовано: (2016-10-01)

New approved drugs for psoriatic arthritis
по: F.M. Perrotta, и др.
Опубликовано: (2016-09-01)

Precision medicine in psoriatic arthritis: how should we select targeted therapies?
по: Al-Mossawi, H, и др.
Опубликовано: (2019)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
по: Ennio Lubrano, и др.
Опубликовано: (2019-08-01)

How should we define disease and outcomes in axial psoriatic arthritis?
по: Coates, LC
Опубликовано: (2021)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
по: Ennio Lubrano, и др.
Опубликовано: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
по: P.S. Helliwell
Опубликовано: (2011-09-01)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
по: Coates, L, и др.
Опубликовано: (2017)

Does treat to target or achieving remission improve radiographic outcome in psa?
по: Coates, L, и др.
Опубликовано: (2016)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
по: Weinstein, SM, и др.
Опубликовано: (2021)

Novel concepts in psoriatic arthritis management: Can we treat to target?
по: Tucker, L, и др.
Опубликовано: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
по: Dures, E, и др.
Опубликовано: (2020)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
по: Ye, W, и др.
Опубликовано: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
по: Gladman, DD, и др.
Опубликовано: (2022)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
по: Helliwell, PS, и др.
Опубликовано: (2023)

Assessment of patient-physician interactions in psoriatic arthritis: national results of the ASSIST Study
по: Perrotta, FM, и др.
Опубликовано: (2024)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
по: Ye, W, и др.
Опубликовано: (2021)

Occult axial involvement in patients with psoriatic arthritis mutilans: a case report
по: F.M. Perrotta, и др.
Опубликовано: (2019-07-01)

Current concepts and unmet needs in psoriatic arthritis
по: Mahmood, F, и др.
Опубликовано: (2017)

Psoriatic arthritis: prospects for the future
по: Hackett, S, и др.
Опубликовано: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
по: Ye, W, и др.
Опубликовано: (2019)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
по: Helliwell, PS, и др.
Опубликовано: (2021)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
по: Coates, L, и др.
Опубликовано: (2016)

Measuring outcomes in psoriatic arthritis
по: Ogdie, A, и др.
Опубликовано: (2020)

Outcome measures in psoriatic arthritis: where next?
по: Hackett, S, и др.
Опубликовано: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
по: Ennio Lubrano, и др.
Опубликовано: (2022-12-01)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
по: Mathew, A, и др.
Опубликовано: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
по: Tucker, L, и др.
Опубликовано: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
по: Mease, PJ, и др.
Опубликовано: (2020)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
по: Helliwell, P, и др.
Опубликовано: (2019)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
по: O'Dwyer, J, и др.
Опубликовано: (2018)

Remission in psoriatic arthritis—where are we now?
по: Coates, L, и др.
Опубликовано: (2017)

Identification of psoriatic arthritis in patients with psoriasis
по: Coates, LC, и др.
Опубликовано: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
по: Soriano, ER, и др.
Опубликовано: (2023)

Psoriatic arthritis: imaging techniques
по: E. Lubrano, и др.
Опубликовано: (2012-06-01)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
по: Coates, L, и др.
Опубликовано: (2018)